Cefotaxime & Sulbactam Injection Manufacturer in India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP manufactures Cefotaxime & Sulbactam Injection for severe bacterial infections requiring high-potency injectable antibiotic therapy in hospitals and critical care units. The formulation is frequently administered in septicemia, respiratory tract infections, intra-abdominal infections, urinary tract complications, and post-surgical bacterial conditions where resistant pathogens are suspected.

Cefotaxime works as a third-generation cephalosporin antibiotic targeting gram-positive and gram-negative bacterial organisms, while Sulbactam enhances antibacterial activity by inhibiting beta-lactamase enzymes responsible for bacterial resistance. This dual-action injectable combination is widely selected in institutional healthcare settings for advanced antibacterial intervention.

As a trusted Cefotaxime & Sulbactam Injection Manufacturer in India, Genliva Wellness LLP operates advanced sterile injectable manufacturing facilities for hospital procurement programs, pharmaceutical distributors, and global antibiotic export markets.

Cefotaxime & Sulbactam Injection is formulated for resistant bacterial infection treatment in hospital settings.

Dual-action cephalosporin injectable antibiotic
Targets beta-lactamase resistant bacterial strains
Commonly utilized in ICU antibacterial therapies
Rapid systemic injectable antibacterial delivery
Manufactured under WHO GMP sterile conditions
Preferred in critical care infection protocols

This injectable formulation is prescribed for severe hospital-acquired and resistant bacterial infections.

Treatment of septicemia and respiratory infections
Management of post-operative bacterial complications
Administered in intra-abdominal infections
Prescribed in urinary tract bacterial conditions
Used in critical care antibacterial therapies
Frequently selected in hospital infection control programs

Cefotaxime & Sulbactam Injection delivers enhanced antibacterial coverage for severe infectious conditions.

Broad antibacterial action against resistant pathogens
Valuable in emergency and ICU infection treatment
Beta-lactamase inhibition improves antibiotic potency
Rapid injectable administration in critical conditions
Widely preferred in institutional healthcare supply